Prophylaxis of upper limb deep vein thrombosis in cancer patients with central vein catheter.

摘要

The clinical benefit of antithrombotic prophylaxis for central vein catheter (CVC)-related deep vein thrombosis (DVT) in cancer patients has never been clearly defined (1-6). Based on published studies, current guidelines do not recommend routine prophylaxis to prevent CVC-related DVT in cancer patients (7).We found of interest the meta-analysis on thromboprophylaxisfor CVC-related DVT in cancer patients recently published in this journal by Chaukiyal et al. (8). This meta-analysis failed to demonstrate a beneficial effect of unfractionated heparin or low-molecular-weight heparin or warfarin (composite relative risk [RR] 0.46, 95% confidence interval [CI] 0.18-1.20, p= 0.06). Of interest, no statistically significant differences were shown in the risk of thrombocytopenia (RR 0.85 95%CI 0.49-1.46, p= 0.55) and bleeding (RR 1.24 95%CI 0.84-1.82, p= 0.28) between patients receiving or not thromboprophylaxis.